Psychiatr Prax 2005; 32(4): 167-171
DOI: 10.1055/s-2004-828330
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Blutbildveränderungen unter Antipsychotika der zweiten Generation

Haematological Abnormalities during Treatment with Atypical AntipsychoticsJohannes  Thome1 , Daniel  Kopf2
  • 1Department of Psychiatry, School of Medicine, University of Wales Swansea
  • 2Zentralinstitut für Seelische Gesundheit, Mannheim
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. April 2005 (online)

Zusammenfassung

Die Gefahr schwerer Blutbildveränderungen stellt einen limitierenden Faktor in der Behandlung mit Clozapin dar. Durch die Entwicklung moderner Antipsychotika der zweiten Generation ist es heute aber möglich, die positiven Effekte dieser Medikamentengruppe zu nutzen, ohne die Risiken einer Clozapin-Behandlung eingehen zu müssen. Allerdings existiert eine Reihe von Kasuistiken, die zeigen, dass auch unter einer Behandlung mit Antipsychotika der zweiten Generation schwere Blutbildveränderungen auftreten können. Die vorliegende Arbeit gibt eine Übersicht über die bisher publizierten Fallberichte und diskutiert die Konsequenzen für die tägliche klinische Praxis.

Abstract

The danger of severe haematological abnormalities limits the use of clozapine in the treatment of psychoses. The development of modern second generation antipsychotics such as olanzapine, risperidone, quetiapine, amisulpride, ziprasidone or aripiprazol, however, makes it possible to use the positive effects of this class of drugs without the risks of a clozapine treatment. Nevertheless, there are several case reports about severe haematological abnormalities even during treatment with these second generation antipsychotics. This review summarises recently published cases and discusses the consequences for the daily clinical work.

Literatur

  • 1 Grohmann R, Rüther E, Sassim N, Schmidt L G. Adverse effects of clozapine.  Psychopharmacology. 1989;  99 S101-S104
  • 2 Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation.  Psychopharmacology. 1989;  99 S118-S121
  • 3 Hohl U, Hoffmann-Richter U. Untypischer Granulozytenabfall unter Clozapinbehandlung.  Psychiat Prax. 1993;  20 232-233
  • 4 Küchenhoff B. Die wichtigsten Nebenwirkungen unter Clozapin (Leponex) und ihre Behandlung.  Psychiat Prax. 1993;  20 201-206
  • 5 Alvir J MJ, Lieberman J A. Agranulocytosis: Incidence and risk factors.  J Clin Psychiat. 1994;  55,9 (Suppl B) 137-138
  • 6 Gerson S L. G-CSF and the management of clozapine-induced agranulocytosis.  J Clin Psychiatry. 1994;  55,9 (Suppl B) 139-142
  • 7 Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker W W. Clozapine-induced transient white blood count disorders.  J Clin Psychiatr. 1994;  55 429-432
  • 8 Alphs L D, Meltzer H Y, Bastani B, Ramirez L F. Side effects of clozapine and their management.  Pharmacopsychiatry. 1991;  24 46
  • 9 Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D. The influence of clozapine treatment on plasma granulocyte colony stimulating (G-CSF) levels.  Pharmacopsychiatry. 1997;  30 118-121
  • 10 Abdullah N, Voronovitch L, Taylor S, Lippmann S. Olanzapine and haloperidol: potential for neutropenia?.  Psychosomatics. 2003;  44 83-84
  • 11 Ahokas A, Elonen E. Circadian rhythm of white blood cells during clozapine treatment.  Psychopharmacology. 1999;  144 301-302
  • 12 Esposito E, Aouillé J, Rouillon F, Limosin F. Morning pseudoneutropenia during clozapine treatment.  World J Biol Psychiatry. 2003;  4 192-194
  • 13 Claas F H, Abbott P A, Witvliet M D, D'Amaro J, Barnes P M, Krupp P. No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis.  Drug Saf. 1992;  7 (Suppl 1) 3-6
  • 14 Amar A, Segman R H, Shtrussberg S, Sherman L, Safirman C, Lerer B, Brautbar C. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201.  Int J Neuropsychopharmacol. 1998;  1 41-44
  • 15 Buchmann N, Strous R D, Ulman A M, Lerner M, Kotler M. Olanzapine-induced leukopenia with human leukocyte antigen profiling.  Int Clin Psychopharmacol. 2001;  16 55-57
  • 16 Guest I, Sokoluk B, MacCrimmon J, Utrecht J. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis.  Toxicology. 1998;  131 54-65
  • 17 Sperner-Unterweger B, Gaggl S, Fleischhacker W W, Barnas C, Herold M, Geissler D. Effects of clozapine on hematopoiesis and the cytokine system.  Biol Psychiatry. 1993;  34 536-543
  • 18 Pisciotta A V, Konings S A. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism.  J Clin Psychiatry. 1994;  55 143-148
  • 19 Schuld A, Kraus T, Hinze-Selch D, Haack M, Pollmächer T. Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.  Acta Psychiatr Scand. 2000;  102 153-155
  • 20 Williams D P, Pirmohamed M, Naisbitt D J, Uetrecht J P, Park B K. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.  Mol Pharmacol. 2000;  58 207-216
  • 21 Croarkin P, Rayner T. Acute neutropenia in a patient treated with quetiapine.  Psychosomatics. 2001;  42 368
  • 22 Palmblad J, Papadaki H A, Eliopoulos G. Acute and chronic neutropenias. What is new?.  J Intern Med. 2001;  250 476-491
  • 23 Loeffler S, Fehsel K, Henning U, Fischer J, Agelink M, Kolb-Bachofen V, Klimke A. Increased apoptosis of neutrophils in a case of clozapine-induced agranulocytoses. A case report.  Pharmacopsychiatry. 2003;  36 37-41
  • 24 Steinwachs A, Grohmann R, Pedrosa F, Rüther E, Schwerdtner I. Two cases of olanzapine-induced neutropenia.  Pharmacopsychiatry. 1999;  32 154-156
  • 25 Benedetti F, Cavallaro R, Smeraldi E. Olanzapine-induced neutropenia after clozapine-induced neutropenia.  Lancet. 1999;  354 567
  • 26 Konakanchi R, Grace J J, Szarowicz R, Pato M T. Olanzapine pronlongation of granulocytopenia after clozapin discontinuation.  J Clin Psychopharmacol. 2000;  20 703-704
  • 27 Swartz J R, Ananth J, Smith M W, Burgoyne K S, Gadasally R, Arai Y. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.  J Clin Psychiatry. 1999;  60 119-121
  • 28 Naumann R, Felber W, Heilemann H, Reuster T. Olanzapine-induced agranulocytosis.  Lancet. 1999;  354 566-567
  • 29 Kodesh A, Finkel B, Lerner A G, Kretzmer G, Sigal M. Dose-dependent olanzapine-associated leukopenia: three case reports.  Int Clin Psychopharmacol. 2001;  16 117-119
  • 30 Gajwani P, Tesar G E. Olanzapine-induced neutropenia.  Psychosomatics. 2000;  41 150-151
  • 31 Etain B, Roubaud L, Heuzey M F Le, Mouren Simeoni M C. Un cas de leucopenie sous traitement par risperidone chez un adolescent.  Encéphale. 2000;  26 81-84
  • 32 Godleski L S, Sernyak M J. Agranulocytosis after addition of risperidone to clozapine treatment.  Am J Psychiatry. 1996;  153 735-736
  • 33 Clark N, Weissberg E, Noel J. Quetiapine and leukopenia.  Am J Psychiatry. 2001;  158 817-818
  • 34 Ruhé H G, Becker H E, Jessurun P, Marees C H, Heeringa M, Vermeulen H D. Agranulocytosis and granulocytopenia associated with quetiapine.  Acta Psychiatr Scand. 2001;  104 311-314
  • 35 Diaz P, Hogan T P. Granulocytopenia with clozapine and quetiapine.  Am J Psychiatry. 2001;  158 651
  • 36 Oluboka O, Haslam D, Lam T, Bown-Demarco D. Quetiapine-induced leukopenia: possible dosage-related phenomenon.  Can J Psychiatry. 2003;  48 65-66
  • 37 Andres E, Maloisel F, Kurtz J E, Kaltenbach G, Alt M, Weber J C, Sibilia J, Schlienger J L, Blickle J F, Brogard J M, Dufour P. Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature.  Eur J Intern Med. 2002;  13 324-328
  • 38 Andres E, Kurtz J E, Maloisel F. Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985 - 2000) and review of the literature.  Clin Lab Haematol. 2002;  24 99-106
  • 39 Safferman A Z, Lieberman J A, Alvir J MJ, Howard A. Rechallenge in clozapine-induced agranulocytosis.  Lancet. 1992;  339 1296-1297
  • 40 Sperner-Unterweger B, Czeipek I, Gaggl S, Geissler D, Spiel G, Fleischhacker W W. Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine.  Br J Psychiatry. 1998;  172 82-84
  • 41 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. 4. Auflage. Berlin u. a.; Springer 2003
  • 42 Hagg S, Rosenius S, Spigset O. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis.  Int Clin Psychopharmacol. 2003;  18 173-174
  • 43 Klimke A, Klieser E. Das atypische Neuroleptikum Clozapin (Leponex®) - aktueller Kenntnisstand und neuere klinische Aspekte.  Fortschr Neurol Psychiat. 1995;  63 173-193

Prof. Dr. med. Dr. phil. Johannes Thome

Department of Psychiatry · School of Medicine · University of Wales Swansea

Grove Building

Singleton Park

Swansea, SA2 8PP

United Kingdom

eMail: j.thome@swan.ac.uk

    >